← Back to Home

Bringing Pathology AI into Slide Review Workflows: Aiforia and PathAI Partner to Expand Distribution of Diagnostic Tools

From quantifying biomarkers to identifying tissue, pathology AI must connect with hospitals’ existing systems to become part of routine diagnosis. The two companies will offer tools and services through a single platform, but this distribution partnership brings no new evidence of clinical performance.

By SURL BioNews

For pathologists, the usefulness of artificial intelligence depends not only on its ability to analyze slides but also on whether its results can flow smoothly into routine slide review workflows. On October 8, 2026, Aiforia announced a commercial agreement with PathAI to provide pathology AI tools to laboratories through AISight Marketplace, giving physicians using PathAI’s platform the opportunity to access these functions within their existing working environment.

The partnership connects two different resources: Aiforia’s portfolio of CE-IVD-marked pathology AI products available in Europe, and PathAI’s existing laboratory customers and presence in the US market. Nordic Life Science reported that Aiforia CEO Jukka Tapaninen identified strengthening the company’s US market presence as a goal of the partnership. For Aiforia, platform distribution is therefore also a way to reach more customers.

The tools address specific tasks in pathology interpretation, including biomarker quantification, tissue classification, and diagnostic decision support. In terms of questions arising during slide review, these concern how much marker signal is present, which tissue category a region in an image belongs to, and which analytical results physicians can refer to when making judgments. However, the announcement did not individually list the models, applicable diseases, or markers included in this offering, so it does not yet provide a basis for describing the full scope of clinical use.

Pathology in Practice reported that Aiforia models will be embedded in case review workflows and will connect to laboratory and hospital information systems through AISight Link; PathAI will handle contracts, billing, and support for the integrated services. This arrangement brings algorithms, information system connections, and procurement services together through a single point of access. From a deployment perspective, it may reduce the coordination burden on healthcare institutions when introducing different tools, but the announcement provided no comparative data on actual implementation time, costs, or work efficiency.

The regulatory scope also needs to be understood separately. The announcement stated that AISight Dx carries a CE-IVD mark for use in primary diagnosis, covering the European Economic Area, Switzerland, and the United Kingdom; Aiforia also already has CE-IVD-marked AI diagnostic products. However, the image management platform and individual analytical models each have their own scope of use. The emphasis on US market expansion in this partnership cannot be taken to mean that all integrated models have obtained US authorization for clinical diagnosis, and the announcement did not disclose any new US regulatory developments.

The substantive advance in this news is that existing pathology AI tools can more easily reach laboratories through a platform. The three announcements and reports published on the same day presented no new clinical validation results and did not specify validation datasets, case numbers, interpretation accuracy, or patient care outcomes. Whether distribution and workflow integration can lead to more reliable diagnoses remains a question to be answered by evidence for each tool in its corresponding use and in actual healthcare settings.

References

  1. Aiforia
  2. Pathology in Practice
  3. Nordic Life Science